182 related articles for article (PubMed ID: 28942664)
1. [Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?].
Sinkó J
Orv Hetil; 2017 Oct; 158(39):1528-1534. PubMed ID: 28942664
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Rodriguez BA; Girotto JE; Nicolau DP
Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
5. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
6. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
7. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
9. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
10. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
Durand CR; Alsharhan M; Willett KC
Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
12. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
Nicolau DP
Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
[TBL] [Abstract][Full Text] [Related]
14. [New antibiotics - standstill or progress].
Rademacher J; Welte T
Med Klin Intensivmed Notfmed; 2017 Apr; 112(3):206-213. PubMed ID: 28314920
[TBL] [Abstract][Full Text] [Related]
15. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
17. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Montravers P; Bassetti M
Curr Opin Infect Dis; 2018 Dec; 31(6):587-593. PubMed ID: 30299359
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
19. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
20. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
Gatti M; Raschi E; De Ponti F
Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1169-1176. PubMed ID: 33415492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
